MedTrace Logo

SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION

NCT06248957 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-02-08

No results posted yet for this study

Summary

The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell/mediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.

Conditions

  • Immunodeficiency
  • Autoimmune Diseases
  • Autoinflammatory Syndrome
  • Allergy
  • Dysregulated Host Response

Interventions

COMBINATION_PRODUCT

Immunomodulation

Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation

Sponsors & Collaborators

  • Karolinska University Hospital

    collaborator OTHER

  • Skane University Hospital

    collaborator OTHER

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Uppsala University Hospital

    collaborator OTHER

  • Region Halland

    collaborator OTHER

  • Region Jönköping County

    collaborator OTHER_GOV

  • Karolinska Institutet

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2030-12-31
Completion
2031-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06248957 on ClinicalTrials.gov